

active form of morphine.”

Please add Claim 4 to read: “The method of claim 1 wherein the peptide is a pharmacologically active form of Substance P.”

**Amendment to the Abstract**

Please amend the Abstract to read:

“The present invention provides a method of transporting a pharmacologically active peptide chimeric hybrid molecules across the blood brain barrier by administration to a living subject of a conjugate molecule comprising the peptide covalently linked to a non-peptide mu (μ) opioid receptor agonist, such as using an opioid moiety of chemically modified morphine (3), that binds to and activates the human mu opioid receptor, with the opioid moiety linked through a novel linker-hinge (4) to the other moiety.”

Respectfully yours,

\_\_\_\_\_  
Richard M. Kream, Ph.D.  
% Chimeracom, LLC  
Wall Street Plaza, 23<sup>rd</sup> Floor  
New York, NY 10005-1875  
Tel: 631-549-2064  
Fax: 212-344-4294

**Certificate of Mailing**

I certify that this correspondence is being filed by fax to 703-872-9306 on the date below.

Date: December 20, 2004

\_\_\_\_\_  
Richard M. Kream, Ph.D.  
Applicant